Amphotericin B for visceral leishmaniasis resistant to pentavalent antimonial drugs in AIDS.
Rodilla
F
F
Magraner
J
J
Aznar
J
J
Orovitg
F
F
Alcácer
F
F
Colomina
J
J
Ferriols
F
F
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000965:Antimony / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D004351:Drug Resistance; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000494:pharmacology*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000494:pharmacology*; D010419:Pentamidine / Q000627:therapeutic use; D015819:Substance Abuse, Intravenous / Q000150:complications
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B; D000965:Antimony